Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600–1609 (2016).
Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223–249 (2021).
Balch, C. M. et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1, 126–134 (2016).
De Martin, E. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 68, 1181–1190 (2018).
Giaccone, G. et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 19, 347–355 (2018).
Adam, K., Iuga, A., Tocheva, A. S. & Mor, A. A novel mouse model for checkpoint inhibitor-induced adverse events. PLoS ONE 16, e0246168 (2021).
Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497–1508 (2016).
Shui, L. et al. Bispecific antibodies: unleashing a new era in oncology treatment. Mol. Cancer 24, 212 (2025).
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H. & Gu, Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 16, 2334–2340 (2016).
Gilardi, M. et al. Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs. Mol. Cancer Ther. 21, 616–624 (2022).
Mikhail, A. S. et al. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer. Adv. Drug Deliv. Rev. 202, 115083 (2023).
Jin, Q. et al. Nanoparticle-mediated delivery of inhaled immunotherapeutics for treating lung metastasis. Adv. Mater. 33, e2007557 (2021).
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & Gajewski, T. F. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 25, 3074–3083 (2019).
Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
Waaler, J. et al. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Commun. Biol. 3, 196 (2020).
DeVito, N. C. et al. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 35, 109071 (2021).
Rodon, J. et al. Phase 1 study of single-agent WNT974, a first-in-class porcupine inhibitor, in patients with advanced solid tumours. Br. J. Cancer 125, 28–37 (2021).
Diamond, J. R. et al. Phase Ib clinical trial of the anti-Frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res. Treat. 184, 53–62 (2020).
Kahn, M. Can we safely target the WNT pathway. Nat. Rev. Drug Discov. 13, 513–532 (2014).
Battistoni, A. et al. Nasal administration of recombinant Neospora caninum secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung. J. Immunother. Cancer 11, e006683 (2023).
Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng 6, 791–805 (2022).
Popowski, K. D. et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 5, 2960–2974 (2022).
Liu, M., Hu, S., Yan, N., Popowski, K. D. & Cheng, K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat. Nanotechnol. 19, 565–575 (2024).
Dinh, P.-U. C. et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 11, 1064 (2020).
Zhang, S. W., Edwards, D. A., Langer, R. & Cheng, K. Inhalable materials and biologics for lung defence and drug delivery. Nat. Rev. Mater. https://doi.org/10.1038/s41578-025-00841-y (2025).
Cheng, K. & Kalluri, R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracell. Ves. 2, 100029 (2023).
Zickler, A. M. & El Andaloussi, S. Functional extracellular vesicles aplenty. Nat. Biomed. Eng 4, 9–11 (2020).
Rayamajhi, S. & Aryal, S. Surface functionalization strategies of extracellular vesicles. J. Mater. Chem. B 8, 4552–4569 (2020).
Gupta, D. et al. Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. Nat. Biomed. Eng 5, 1084–1098 (2021).
Dooley, K. et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. Mol. Ther. 29, 1729–1743 (2021).
Jeppesen, D. K. et al. Reassessment of exosome composition. Cell 177, 428–445 (2019).
Kugeratski, F. G. et al. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat. Cell Biol. 23, 631–641 (2021).
Simpson, R. J., Kalra, H. & Mathivanan, S. ExoCarta as a resource for exosomal research. J. Extracell. Vesicles 1, 18374 (2012).
Lee, K. M., Seo, E. C., Lee, J. H., Kim, H. J. & Hwangbo, C. The multifunctional protein syntenin-1: regulator of exosome biogenesis, cellular function, and tumor progression. Int. J. Mol. Sci. 24, 9418 (2023).
Hurley, J. H. & Odorizzi, G. Get on the exosome bus with ALIX. Nat. Cell Biol. 14, 654–655 (2012).
Li, S. P., Lin, Z. X., Jiang, X. Y. & Yu, X. Y. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol. Sin. 39, 542–551 (2018).
Marquez-Rodas, I. et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann. Transl. Med. 3, 267 (2015).
Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002–1014 (2021).
Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077–3085 (2009).
Ji, R.-R. et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019–1031 (2012).
Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
Li, Y. et al. N-Myc downstream-regulated gene 2, a novel estrogen-targeted gene, is involved in the regulation of Na+/K+-ATPase. J. Biol. Chem. 286, 32289–32299 (2011).
Khuu, C. H., Barrozo, R. M., Hai, T. & Weinstein, S. L. Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages. Mol. Immunol. 44, 1598–1605 (2007).
Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311–325 (2017).
Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing BATF3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, e714 (2017).
Reschke, R. et al. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J. Immunother. Cancer 9, e003521 (2021).
Padovan, E., Spagnoli, G. C., Ferrantini, M. & Heberer, M. IFN-α2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J. Leukoc. Biol. 71, 669–676 (2002).
Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018).
Poggio, M. et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell 177, 414–427 (2019).
Yang, Y. et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 28, 862–864 (2018).
Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. & Garcia, K. C. Structural basis of Wnt recognition by Frizzled. Science 337, 59–64 (2012).
Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012).
Peng, W. et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 72, 5209–5218 (2012).
Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).
Corso, G. et al. Systematic characterization of extracellular vesicle sorting domains and quantification at the single molecule–single vesicle level by fluorescence correlation spectroscopy and single particle imaging. J. Extracell. Vesicles 8, 1663043 (2019).
Parsons, M. J., Tammela, T. & Dow, L. E. WNT as a driver and dependency in cancer. Cancer Discov. 11, 2413–2429 (2021).
Gajos-Michniewicz, A. & Czyz, M. WNT signaling in melanoma. Int. J. Mol. Sci. 21, 4852 (2020).
Li, S. et al. PIF1 helicase promotes break-induced replication in mammalian cells. EMBO J. 40, e104509 (2021).
Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).
McDermott, S. P., Eppert, K., Lechman, E. R., Doedens, M. & Dick, J. E. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 116, 193–200 (2010).
Liu, S. et al. DNA repair protein RAD52 is required for protecting G-quadruplexes in mammalian cells. J. Biol. Chem. 299, 102770 (2023).
Zhenilo, S. et al. DeSUMOylation switches Kaiso from activator to repressor upon hyperosmotic stress. Cell Death Differ. 25, 1938–1951 (2018).
Liu, S. et al. FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction. Cell Death Dis. 11, 804 (2020).
Hugo W. et al. mRNA expressions in pre-treatment melanomas undergoing anti-PD-1 checkpoint inhibition therapy. Gene Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78220 (2016).
